Arcus Biosciences (RCUS) Stock Forecast & Price Target

Arcus Biosciences is viewed favorably because casdatifan is building a compelling clinical profile across ccRCC, with durable late-line monotherapy survival, strong frontline disease control, and encouraging combination activity that collectively suggest best-in-class potential versus belzutifan. The second-line casdatifan-plus-cabozantinib data were mixed on PFS, but 44% ORR, 14.5-month mPFS, and supportive OS landmarks, plus activity in prior-TKI patients, help validate the ongoing PEAK-1 thesis and de-risk broader adoption. With PEAK-20 on track for 4Q:26, additional registrational studies planned, and projected peak ccRCC revenue around $3.2B, the company has multiple paths to expand casdatifan across the disease continuum.

Arcus Biosciences is viewed negatively because its valuation depends heavily on clinical and regulatory success, yet the company faces meaningful risk that AB154 and domvanalimab may fail to demonstrate sufficient efficacy or could raise safety concerns that halt development. Even if the pipeline advances, the company may struggle to achieve sales estimates, especially if competing therapies in cancer and other indications prove more effective or capture physician and payer adoption. With only one operating segment focused on developing and commercializing differentiated therapies, Arcus remains highly exposed to pipeline concentration, making any setback in development or commercialization disproportionately damaging to the investment case.